Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.

Long gone are the days when Moderna (NASDAQ: MRNA) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple of years, the company's revenue and earnings have plummeted along with its stock price.Moderna is eager to prove its success wasn't just a one-off. And the company could achieve that goal in the next five years, leading to substantial stock-market returns over this period.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool